Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Articles

Phase I Trial of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil plus Interferon-α2b in Patients with Advanced Breast Cancer

Joseph A. Sparano, Scott Wadler, Leonard Liebes, Nicholas J. Robert, Edward L. Schwartz and Janice P. Dutcher
Joseph A. Sparano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Wadler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonard Liebes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas J. Robert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward L. Schwartz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janice P. Dutcher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published August 1993
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

α-Interferon (IFN-α) enhances the activity of 5-fluorouracil in patients with advanced colorectal carcinoma. Preclinical evidence suggests a similar potential role for IFN-α combined with cyclophosphamide, doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and 5-fluorouracil (CAF) in advanced adenocarcinoma of the breast. To determine a maximum tolerated dose of IFN-α that could be combined with CAF and that did not compromise CAF dose intensity and to determine the effect of IFN-α on the pharmacokinetics of doxorubicin, a phase I study of IFN-α plus CAF was performed by the Eastern Cooperative Oncology Group. Nine patients with advanced breast cancer received CAF (cyclophosphamide at 100 mg/m2/day p.o. on days 1–14, doxorubicin at 30 mg/m2 and 5-fluorouracil at 500 mg/m2 i.v. bolus on days 1 and 8) plus IFN-α (1 milliunit/m2, n = 6, or 2 milliunits/m2, n = 3) given s.c. on days 1, 3, 5, and 8 (1 h prior to the doxorubicin and 5-FU injection on days 1 and 8) of each cycle every 28 or more days. Escalation of the IFN-α dose occurred in cohorts of 3–6 patients if a dose-limiting toxic event (neutropenic fever, platelet nadir of < 25,000/µl, > 2-week treatment delay, or a >50% dose reduction in day 8 CAF) occurred during the first two cycles in 0 of 3 or 1 of 6 patients. During cycle 1, IFN-α was omitted on day 1, and multiple plasma samples were drawn on day 1 (without IFN-α) and day 8 (with IFN-α) after each doxorubicin injection and were analyzed for plasma doxorubicin concentration. The maximum tolerated dose of IFN-α by our criteria was 1 milliunit/m2, and neutropenia was the predominant toxic effect that precluded IFN-α dose escalation. The dose intensity of CAF achieved with IFN-α was identical to that for CAF alone observed in prior studies. IFN-α had no significant effect on the pharmacokinetics of doxorubicin, although 3 of 7 patients studied had reduced doxorubicin clearance, ranging from 32% to 69%. Alternative CAF drug delivery schedules (all drugs given i.v. every 3–4 weeks) that are more amenable to hematopoietic growth factor support may be more suitable to combine with higher doses of IFN-α that may produce modulation.

Footnotes

  • ↵1 Supported in part by the National Cancer Institute, Department of Health and Human Services Grants P30CA13330 and 5U10CA14958, and by American Cancer Society Career Development Award 92-274 (J. A. S.).

  • ↵2 To whom requests for reprints should be addressed, at Albert Einstein Cancer Center, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467.

  • Received April 15, 1993.
  • Accepted May 24, 1993.
  • ©1993 American Association for Cancer Research.
PreviousNext
Back to top
August 1993
Volume 53, Issue 15
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phase I Trial of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil plus Interferon-α2b in Patients with Advanced Breast Cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Phase I Trial of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil plus Interferon-α2b in Patients with Advanced Breast Cancer
Joseph A. Sparano, Scott Wadler, Leonard Liebes, Nicholas J. Robert, Edward L. Schwartz and Janice P. Dutcher
Cancer Res August 1 1993 (53) (15) 3509-3512;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phase I Trial of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil plus Interferon-α2b in Patients with Advanced Breast Cancer
Joseph A. Sparano, Scott Wadler, Leonard Liebes, Nicholas J. Robert, Edward L. Schwartz and Janice P. Dutcher
Cancer Res August 1 1993 (53) (15) 3509-3512;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The Role of Chimeric Paired Box Transcription Factors in the Pathogenesis of Pediatric Rhabdomyosarcoma
  • Tissue Structure, Nuclear Organization, and Gene Expression in Normal and Malignant Breast
  • Laureate Citations
Show more Articles
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement